CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China’s National Medical Products Administration

CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

CANbridge Pharmaceuticals CEO, James Xue, Named as Termeer Foundation Mentor

Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases

CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery and Editing Platforms

First Subject Dosed in CANbridge Pharmaceuticals CAN106 Trial for Treatment of Complement Dysregulation Diseases in Singapore

CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration

CANbridge Pharmaceuticals Appoints General Manager of China

CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in Singapore for the Treatment of Complement Dysregulation Diseases